ED
ABMD

Exane Derivatives’s Abiomed Inc ABMD Stock Holding History

Exane Derivatives’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-236
Closed -$34.3K – 752
2020
Q1 		$34.3K Hold
236
– – 0.01% 385
2019
Q4 		$42K Hold
236
– – 0.01% 364
2019
Q3 		$42K Hold
236
– – 0.01% 376
2019
Q2 		$61.5K Buy
+236
New +$62.6K 0.01% 373

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Exane Derivatives's ABMD Position: Q2 2020 in Review

Exane Derivatives sold out of Abiomed Inc (ABMD) in Q2 2020, closing a stake of 236 shares — an estimated $34.3K sold.

Exane Derivatives first reported a position in ABMD in Q2 2019 and held it in 4 quarters. The position peaked at $61.5K in Q2 2019. 460 funds tracked by Wall St. Rank hold ABMD as of Q2 2020.

  • Exane Derivatives reported no remaining Abiomed Inc position as of Q2 2020 after selling out during the quarter.
  • Exane Derivatives sold 236 Abiomed Inc shares in Q2 2020, an estimated $34.3K.
  • Exane Derivatives first reported a position in Abiomed Inc in Q2 2019 and held it in 4 quarters.
  • Exane Derivatives's Abiomed Inc position peaked at $61.5K in Q2 2019.
  • 460 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.